Listed below are the Topics in Antiviral Medicine Editorial Board members and their financial relationships with ineligible companies within the past 24 months from the date of disclosure. Members of the TAM Editorial Board are compensated for their work on the journal.
The ACCME defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
Editor in Chief
Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California San Diego
La Jolla, California
Dr Richman reported no relevant financial relationships with ineligible companies. (Updated May 15, 2026)
Members
Constance A. Benson, MD
Professor of Medicine
University of California San Diego
San Diego, California
Dr Benson reported grants/grants pending to her institution from BioMerieux (Updated May 15, 2026)
Martin S. Hirsch, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Dr Hirsch reported no relevant financial affiliations with ineligible companies.(Updated June 8, 2026)